Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease.

[Guest guest]

Hi All,

Again we see oxidized LDL is highly involved in the pathway of atherosclerotic

coronary artery disease (CAD). The body

even makes an anti-body against it and by measuring the level of this anti-body,

both the present and level of CAD as

well as the level of plaque instability can be determined.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve & db=PubMed & list_uids=1\

1693751 & dopt=Abstract

J Am Coll Cardiol 2001 Mar 1;37(3):775-9 Related Articles, Books, LinkOut

Clinical significance of antibody against oxidized low density lipoprotein in

patients with atherosclerotic coronary

artery disease.

Inoue T, Uchida T, Kamishirado H, Takayanagi K, Hayashi T, Morooka S.

Department of Cardiology, Koshigaya Hospital, Dokkvo University School of

Medicine, Saitama, Japan.

inouet@...

OBJECTIVES:

This study was designed to establish the clinical significance of antibodies

against oxidized low density lipoprotein

(anti-Ox-LDL) titer in atherosclerotic coronary artery disease (CAD).

BACKGROUND:

Oxidative modification of LDL, which plays a key role in the development of

atherosclerosis, induces immunogenic

epitopes in the LDL molecule, and the presence of anti-Ox-LDL has been

demonstrated in human sera.

METHODS:

Anti-Ox-LDL titer was measured by enzyme-linked immunosorbent assay in 108

patients who had angiographically verified

CAD, and 31 patients who had chest pain but no significant CAD, as controls.

RESULTS:

The anti-Ox-LDL titer was higher (p < 0.01) in patients with multivessel CAD

(19.4 +/- 10.1 AcU/ml, n = 68) than in the

controls (9.8 +/- 4.1). However, no significant difference was shown between the

single-vessel CAD group (15.1 +/- 6.4,

n = 40) and the controls, or between the multivessel CAD group and the

single-vessel CAD group. The titer was higher in

patients with unstable angina (21.5 +/- 11.8 AcU/ml, n = 20, p < 0.01), or in

patients with acute myocardial infarction

(23.1 +/- 12.0, n = 20, p < 0.01) than in patients with stable-effort angina or

old myocardial infarction (12.2 +/- 8.6,

n = 68). Multiple logistic regression analysis indicated that the anti-Ox-LDL

titer most powerfully discriminated CAD

patients from controls (odds ratio [OR]: 1.20, 95% confidence interval [CI]:

1.07-1.33, p = 0.0006) and acute coronary

syndrome from chronic CAD (OR: 1.09, 95% CI: 1.04-1.14, p = 0.0008).

CONCLUSIONS:

Serum anti-Ox-LDL titer not only can predict a presence of atherosclerotic CAD

but also may be a marker of plaque

instability. Low density lipoprotein [LDL..gw] oxidation may play an important

role in the development of plaque

instability.

PMID: 11693751 [PubMed - indexed for MEDLINE]

========================

Good Health & Long Life,

Greg , http://optimalhealth.cia.com.au gowatson@...

USDA database (food breakdown) http://www.nal.usda.gov/fnic/foodcomp/

PubMed (research papers) http://www.ncbi.nlm.nih.gov/entrez/query.fcgi

DWIDP (nutrient analysis) http://www.walford.com/dwdemo/dw2b63demo.exe

Patch file for above http://www.walford.com/download/dwidp67u.exe

KIM (omega analysis) http://ods.od.nih.gov/eicosanoids/KIM_Install.exe